Trial Profile

A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2019 According to a Cognition Therapeutics media release, top-line results from the study had been presented at the 9th Annual Clinical Trials on Alzheimer's Disease (CTAD) meeting.
19 Feb 2019 According to a Cognition Therapeutics media release, final results from the study were published in Alzheimer's & Dementia: Translational Research & Clinical Interventions.
19 Feb 2019 Final results published in a Cognition Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com